Singapore markets close in 3 hours 18 minutes
  • Straits Times Index

    3,292.92
    -1.90 (-0.06%)
     
  • Nikkei

    27,399.21
    -373.72 (-1.35%)
     
  • Hang Seng

    24,763.79
    -188.56 (-0.76%)
     
  • FTSE 100

    7,585.01
    -4.65 (-0.06%)
     
  • BTC-USD

    38,857.50
    -3,004.23 (-7.18%)
     
  • CMC Crypto 200

    917.61
    -77.65 (-7.80%)
     
  • S&P 500

    4,482.73
    -50.03 (-1.10%)
     
  • Dow

    34,715.39
    -313.26 (-0.89%)
     
  • Nasdaq

    14,154.02
    -186.23 (-1.30%)
     
  • Gold

    1,840.50
    -2.10 (-0.11%)
     
  • Crude Oil

    86.29
    -0.61 (-0.70%)
     
  • 10-Yr Bond

    1.8330
    0.0000 (0.00%)
     
  • FTSE Bursa Malaysia

    1,523.78
    -3.97 (-0.26%)
     
  • Jakarta Composite Index

    6,662.74
    +35.87 (+0.54%)
     
  • PSE Index

    7,293.52
    +54.24 (+0.75%)
     
DEALS:

Singtel takes 16.3% stake in Indonesia's Bank Fama for S$48 million

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Third Quarter 2021 Financial Results and Provide Corporate Update

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.
  • XENE

BURNABY, British Columbia, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its third quarter 2021 financial and operating results after the close of U.S. financial markets on Wednesday, November 10, 2021.

  • Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) on Wednesday, November 10, 2021 to discuss the third quarter 2021 financial results and provide a corporate update. The webcast will be broadcast live on the Investors section of the Xenon website. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 1244439.

The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at investor.xenon-pharma.com. When available, webcasts will be posted for replay following the event.

About Xenon Pharmaceuticals Inc.

We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Maria McClean
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: investors@xenon-pharma.com


Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting